Journal of Turkish Clinical Biochemistry

The official publication of Turkish Society of Clinical Biochemistry

Diamond OA
No APCs
First Decision
30 Days
Indexed In
TR Dizin
Original Research
December 01, 2020
JTCB. 2020 Dec 1; 18 (3) : 150-156

Evaluation of κ and λ light chain expressions by flow cytometry analysis in cases of CLL

1 Afyonkarahisar Sağlık Bilimleri Üniversitesi Tıp Fakültesi, Tıbbi Patoloji AD., Afyonkarahisar, Türkiye
2 Afyonkarahisar Sağlık Bilimleri Üniversitesi Tıp Fakültesi, İç Hastalıkları AD, Hematoloji BD, Afyonkarahisar, Türkiye
3 Afyonkarahisar Sağlık Bilimleri Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya AD., Afyonkarahisar, Türkiye

Abstract

Objective: Confirmation of the clonality of B lymphocytes by flow cytometry analysis has an important role in the diagnosis of Chronic Lymphocytic Leukemia (CLL). In this retrospective study, we investigated which surface light chain pattern they showed as indicative of the monoclonity of CLL cells.

Material and Methods: Flow cytometry results of 33 CLL patients (12 women / 21 men) were examined retrospectively. The reading results of the samples obtained after the application of the antibodies in the CLL immunophenotyping panel and the lysing procedure were evaluated. Cells that co-express CD19 and CD5 were considered CLL cells, and kappa and lambda light chain expressions were evaluated to the monoclonity of these cells.

Results: When all cases were evaluated, the percentage of cases showing kappa monoclonity was 30.3%, while the percentage of cases showing lambda monoclonity was 51.5%. It was observed that both light chain expressions were absent in 18.2% of cases.

Conclusion: In our patients, lambda light chain restriction was observed most frequently in CLL cells.

Citation

Özdemir, Çiğdem, Filiz Yavaşoğlu, and Tülay Köken. 2020. “Evaluation of κ and λ Light Chain Expressions by Flow Cytometry Analysis in Cases of CLL”. Journal of Turkish Clinical Biochemistry 18 (3):150-56. https://turkclinbiochem.org/index.php/pub/article/view/376.

Publish with JTCB

Diamond Open Access

Fully Diamond OA with no APCs and no submission fees. Your research is freely available to readers worldwide from the day it publishes.

30-Day First Decision

Double-blind peer review from an active editorial team returns a first decision in about 30 days, keeping your manuscript moving.

Global Platform

Backed by the Turkish Society of Clinical Biochemistry, JTCB welcomes submissions from researchers worldwide and reaches an international laboratory audience.

Focused Laboratory Scope

Method validation, analyzer comparisons, reference intervals, quality indicators, preanalytical studies, and instructive clinical case reports.

Credible and Discoverable

All manuscripts publish in English and follow ICMJE and COPE guidelines, with Crossref DOIs and TR Dizin indexing ensuring global discoverability.